key: cord-0879370-a6s2f3ex
authors: Tanaka, Fumika; Katayama, Kan; Joh, Kensuke; Tsujimoto, Kayo; Yamawaki, Masahiro; Saiki, Ryosuke; Kurita, Tairo; Murata, Tomohiro; Dohi, Kaoru
title: Minimal change disease with thrombotic microangiopathy following the Pfizer-BioNTech COVID-19 vaccine
date: 2021-11-22
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab234
sha: 3d6254eb1899d5065b47ce77ddff62bbdbb546eb
doc_id: 879370
cord_uid: a6s2f3ex

nan

There have been reports of minimal change disease (MCD) following the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine. [1] [2] [3] [4] [5] Here we report a case of MCD with mesangiolysis after Pfizer-BioNTech vaccination.

A 69-year-old Japanese woman received the first injection of the BNT 162b2 COVID-19 39 days before a kidney biopsy. While she had been taking amlodipine for hypertension and rosuvastatin for hyperlipidemia, she had never demonstrated kidney dysfunction. Although she noticed bilateral mild leg edema 7 days after the first vaccination, she continued to receive the second injection 18 days before the kidney biopsy. The next day,

she had a fever of 37.5 °C and took a tablet of loxoprofen, which relieved her symptom. Her bilateral leg edema subsequently worsened, and her body weight increased 4 kg from her usual weight. She visited a local doctor 9 days prior to our encounter, and her serum albumin was 1.4 g/dL. Nephrotic syndrome was suspected, and a tablet of azosemide 30 mg was prescribed. However, her edema did not improve, and she was referred to our hospital for a further evaluation.

Her height, body weight, and blood pressure were 155 cm, 57.5 kg, and 120/80 mmHg, respectively. A physical examination revealed bilateral pitting edema in her lower legs. The urinary protein/creatinine ratio, serum albumin, and serum creatinine were 8.08

g/gCr, 1.5 g/dL, and 0.65 mg/dL, respectively. The selectivity index was low at 0.15. 

Post-vaccinal minimal change disease

Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine

An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

Report of Three Cases of Minimal Change Disease Following the Second Dose of mRNA SARS-CoV-2 COVID-19 Vaccine

Nephrotic Syndrome Following ChAdOx1 nCoV-19 Vaccine Against SARScoV-2

Renal Thrombotic Microangiopathy in Concurrent COVID-19 Vaccination and Infection

The authors declare no competing interests in association with the present study. The results presented in this paper have not been published previously in whole or part.